This site uses cookes. By using this site you are consenting to their use according to our Cookie policy.

i agree

Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes

Funding Agency: European Commission

Funding Programme: Horizon 2020

Call/Topic: H2020-PHC-2014-single-stage

Project Reference: 643776

Start Date: 2015.01.01

Duration: 60 months

Total Investment: EUR 5 899 250 (EU contribution: EUR 5 899 250)

Project Coordinator: João Lacerda

Project Beneficiaries:

  • Instituto de Medicina Molecular João Lobo Antunes (iMM), Portugal;
  • Klinikum der Universitaet Regensburg, Germany;
  • Universite de Liege, Belgium;
  • Azienda Ospedaliero Universitaria Policlinico S. Orsola Malpighi, Italy;
  • Max-Planck-Gesellschaft zur Forderung der Wissenschaften EV, Germany;
  • Alacris Theranostics GMBH, Germany;
  • The University of Liverpool, United Kingdom;

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643776.

More Information


This project encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versushost disease (GVHD) after hematopoietic stem cell transplantation (HSCT).

We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivoisolated Treg are sufficient or whether in vitroexpansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy.

The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells.

Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.